Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 24, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,490,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 24, 2013.
- Price Range: Highest price paid was 1,606 pence per share; lowest price paid was 1,594.50 pence per share.
- Treasury Holdings (Settled): 473,879,412 shares (8.83% of total issued share capital).
- Treasury Holdings (Including Unsettled): 478,154,412 shares (9.78% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,891,172,303 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,490,000 shares. Consequently, the percentage of shares held in Treasury increased to 8.83% of issued capital and 9.78% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,891,172,303) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (473,879,412 settled) for voting rights calculations.
- Note that the repurchase price range (1,594.50 to 1,606 pence) reflects market conditions on September 24, 2013.